INS and type 2 diabetes mellitus: An RCT by Ehrhardt et al. randomized 100 patients with T2D on various therapies, excluding prandial insulin to either usual care or four cycles of rtCGM (Dexcom SEVEN, 2 weeks on/1 week off) over 12 weeks.23 After 12 weeks, all subjects were followed by their primary care providers for an additional 40 weeks.